BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luo Y, Alexander M, Gadina M, O'Shea JJ, Meylan F, Schwartz DM. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. J Allergy Clin Immunol 2021;148:911-25. [PMID: 34625141 DOI: 10.1016/j.jaci.2021.08.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Aung WW, Hamaguchi Y, Matsushita T. Targeting cytokines and potentiality of JAK–STAT inhibition in systemic sclerosis. J Cutaneous Imm & Allergy 2022. [DOI: 10.1002/cia2.12288] [Reference Citation Analysis]
2 Yang F, Zhang A. Involvement of METTL3 in arsenite-induced skin lesions by targeting the SOCS3/STAT3/Krt signaling pathway. Environmental Pollution 2022. [DOI: 10.1016/j.envpol.2022.120634] [Reference Citation Analysis]
3 Zhu M, Li S, Cao X, Rashid K, Liu T. The STAT family: key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.11.011] [Reference Citation Analysis]
4 Zhao L, Hou C, Yan N. Neuroinflammation in retinitis pigmentosa: Therapies targeting the innate immune system. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1059947] [Reference Citation Analysis]
5 Chen J, Xiao-yun Tian, Wei S, Yang Y, Deng S, Jiao C, Wang C, Chu K, Ma X, Xu W. Perspectives of herbs and their natural compounds, and herb formulas on treating diverse diseases through regulating complicated JAK/STAT signaling. Front Pharmacol 2022;13:993862. [DOI: 10.3389/fphar.2022.993862] [Reference Citation Analysis]
6 Tanboon J, Nishino I. Update on dermatomyositis. Curr Opin Neurol 2022. [PMID: 35942671 DOI: 10.1097/WCO.0000000000001091] [Reference Citation Analysis]
7 Huang J, Zhou C, Deng J, Zhou J. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Biochem Pharmacol 2022;:115162. [PMID: 35787993 DOI: 10.1016/j.bcp.2022.115162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Basheer F, Bulleeraz V, Ngo VQT, Liongue C, Ward AC. In vivo impact of JAK3 A573V mutation revealed using zebrafish. Cell Mol Life Sci 2022;79:322. [PMID: 35622134 DOI: 10.1007/s00018-022-04361-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sharma M, Lu HY, Vaseghi-shanjani M, Del Bel KL, Fornes O, van der Lee R, Richmond PA, Lin S, Dalmann J, Lee JJ, Matthews A, Blanchard-rohner G, van Karnebeek CDM, Bedford HM, Wasserman WW, Seear M, Mckinnon ML, Ahmed H, Turvey SE. Human Germline Heterozygous Gain-of-Function STAT6 Variants Cause Severe Allergic Disease.. [DOI: 10.1101/2022.04.25.22274265] [Reference Citation Analysis]
10 Marcuzzi A, Rimondi E, Melloni E, Gonelli A, Grasso AG, Barbi E, Maximova N. Early Use of Low-Dose Ruxolitinib: A Promising Strategy for the Treatment of Acute and Chronic GVHD. Pharmaceuticals 2022;15:374. [DOI: 10.3390/ph15030374] [Reference Citation Analysis]
11 Glassman CR, Tsutsumi N, Saxton RA, Lupardus PJ, Jude KM, Garcia KC. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science 2022;:eabn8933. [PMID: 35271300 DOI: 10.1126/science.abn8933] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
12 Tamarit-sebastian S, Ferrer-soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]